NewAmsterdam Pharma completes enrollment for Phase 3 TANDEM trial

NewAmsterdam Pharma announced the completion of patient enrollment in the pivotal Phase 3 TANDEM clinical trial evaluating the fixed-dose combination of obicetrapib plus ezetimibe in adult patients with Heterozygous Familial Hypercholesterolemia and/or Atherosclerotic Cardiovascular Disease or multiple risk factors for ASCVD, whose LDL-C is not adequately controlled despite being on maximally tolerated lipid-modifying therapies. “Completing enrollment of the pivotal Phase 3 TANDEM trial marks an important step in our mission of advancing obicetrapib through late-stage clinical development and brings us closer to delivering a simple and convenient once-daily tablet to the millions of people suffering from dyslipidemia,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma. “With positive enrollment trends observed in four ongoing contemporaneous pivotal Phase 3 studies – BROOKLYN, BROADWAY, PREVAIL and TANDEM – we continue to be encouraged by physician and patient interest in our clinical trials, which we believe reflects growing awareness of our CETP inhibitor and its potential ability to address elevated LDL-C and improve health outcomes for millions of patients globally, if approved. We look forward to sharing topline data from the TANDEM study in the first quarter of 2025.”